Ipriflavone

Ipriflavone
Clinical data

AHFS/Drugs.com	International Drug Names
ATC code	M05BX01 (WHO)
Identifiers
IUPAC name 7-isopropoxy-3-phenyl-4H-chromen-4-one
Synonyms	3-phenyl-7-propan-2-yloxychromen-4-one
CAS Number	35212-22-7^N
PubChem (CID)	3747
ChemSpider	3616^N
UNII	80BJ7WN25Z^Y
KEGG	D01338^Y
ChEMBL	CHEMBL165790^N
ECHA InfoCard	100.125.854
Chemical and physical data
Formula	C₁₈H₁₆O₃
Molar mass	280.318 g/mol
3D model (Jmol)	Interactive image
SMILES CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
InChI InChI=1S/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3^N Key:SFBODOKJTYAUCM-UHFFFAOYSA-N^N
^NY (what is this?) (verify)

Ipriflavone is a synthetic isoflavone which may be used to inhibit bone resorption,^[1] maintain bone density and to prevent osteoporosis in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.

A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis.^[2]

A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers.^[3]

References

↑ Civitelli, R. (1997). "In Vitro and in Vivo effects of ipriflavone on bone formation and bone biomechanics". Calcified Tissue International. 61: S12–4. doi:10.1007/s002239900378. PMID 9263610.
↑ Alexandersen, P.; Toussaint, A; Christiansen, C; Devogelaer, JP; Roux, C; Fechtenbaum, J; Gennari, C; Reginster, JY; Ipriflavone Multicenter European Fracture Study (2001). "Ipriflavone in the Treatment of Postmenopausal Osteoporosis: A Randomized Controlled Trial". JAMA. 285 (11): 1482–8. doi:10.1001/jama.285.11.1482. PMID 11255425.
↑ Sziklai, I; Komora, V; Ribári, O (1992). "Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis". Acta chirurgica Hungarica. 33 (1–2): 101–7. PMID 1343452.

External links

Ipriflavone at PDR Health

Drugs for treatment of bone diseases (M05)

Bisphosphonates	Nitrogenous (Alendronic acid ibandronic acid incadronic acid pamidronic acid risedronic acid zoledronic acid) Non-nitrogenous (Etidronic acid clodronic acid tiludronic acid)

Bone morphogenetic proteins	Dibotermin alfa Eptotermin alfa

Other	Resorption inhibitor (Ipriflavone) Aluminium chlorohydrate Dual action bone agent (Strontium ranelate) RANKL inhibitor (Denosumab) Cathepsin K inhibitor (Odanacatib) Calcium Vitamin D

Isoflavones and their glycosides

Isoflavones	Daidzein Genistein Irilone Orobol Pseudobaptigenin Anagyroidisoflavone A and B

O-methylated isoflavones	Biochanin A Calycosin Formononetin Glycitein Irigenin 5-O-methylgenistein Pratensein Prunetin Psi-tectorigenin Retusin Tectorigenin

Glycosides	Daidzin Genistin Iridin Ononin Puerarin Sophoricoside Tectoridin

Prenylated isoflavones	Bidwillol A Derrubone Luteone 7-O-Methylluteone Wighteone

Pyranoisoflavones	Alpinumisoflavone Barbigerone Di-O-methylalpinumisoflavone 4'-methyl-alpinumisoflavone

Misc	Rotenoids

Synthetic	Ipriflavone

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.